首页> 外文期刊>Drug Design, Development and Therapy >Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system
【24h】

Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system

机译:使用负载利多卡因的纳米结构脂质载体进行局部麻醉治疗:生育酚聚乙二醇1000琥珀酸酯修饰的透皮给药系统

获取原文
           

摘要

Purpose: Transdermal drug delivery of local anesthetics using lipid nanoparticles could enhance lipophilic drugs permeation through the stratum corneum, improve drug diffusion to deeper skin, and exert good therapeutic effects. The purpose of this study was to engineer a Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS)-modified cationic nanostructured lipid carriers (NLC) for the delivery of lidocaine (LID; TPGS/LID-NLC). Materials and methods: TPGS/LID-NLC was prepared by solvent diffusion method. The particle size, polydispersity index, zeta potential, drug entrapment efficiency, drug loading, stability, drug release, and cytotoxicity were tested to evaluate the basic characters of NLC. In vitro skin permeation and in vivo anesthesia effect in an animal model were further investigated to determine the therapeutic efficiency of the system. Results: TPGS/LID-NLC had a particle size of 167.6±4.3 nm, a zeta potential of?+21.2±2.3 mV, an entrapment efficiency of 85.9%±3.1%, and a drug loading of 11.5%±0.9%. A sustained release pattern was achieved by TPGS/LID-NLC, with 81.2% of LID released at 72 hours. In vitro permeation study showed that the steady-state fluxes (Jss), permeability coefficient (Kp), and cumulative drug permeation Qn at 72 hours (Q72) of TPGS/LID-NLC were 15.6±1.8 μg/cm2/hour, 10.3±0.9 cm/hour (×10-3), and 547.5±23.6 μg/cm2, respectively, which were significantly higher than the nonmodified NLC and free drug groups. In vivo anesthesia effect of TPGS/LID-NLC was the most remarkable and long acting among the formulations tested, which could be concluded by the most considerable maximum possible effect from 10 to 120 minutes during the whole research. Conclusion: The most prominent in vitro permeation efficiency and in vivo anesthetic effect of TPGS/LID-NLC could be the evidence that TPGS-modified NLC could function as a promising drug delivery system for prolonged and efficient local anesthetic therapy.
机译:目的:使用脂质纳米粒透皮给药局部麻醉药可以增强亲脂性药物通过角质层的渗透,改善药物向深层皮肤的扩散,并发挥良好的治疗作用。这项研究的目的是设计一种生育酚聚乙二醇1000琥珀酸酯(TPGS)改性的阳离子纳米结构脂质载体(NLC),用于递送利多卡因(LID; TPGS / LID-NLC)。材料与方法:TPGS / LID-NLC采用溶剂扩散法制备。测试了粒径,多分散指数,ζ电势,药物截留效率,药物载量,稳定性,药物释放和细胞毒性,以评估NLC的基本特性。进一步研究了动物模型中的体外皮肤渗透和体内麻醉作用,以确定该系统的治疗效率。结果:TPGS / LID-NLC的粒径为167.6±4.3nm,ζ电势为±21.2±2.3mV,包封率为85.9%±3.1%,载药量为11.5%±0.9%。 TPGS / LID-NLC实现了持续释放,在72小时释放了81.2%的LID。体外渗透研究表明,TPGS / LID-NLC在72小时(Q72)的稳态通量(Jss),渗透系数(Kp)和累积药物渗透Qn为15.6±1.8μg/ cm2 / hour,10.3±分别为0.9 cm / hour(×10-3)和547.5±23.6μg/ cm2,显着高于未修饰的NLC和游离药物组。 TPGS / LID-NLC的体内麻醉作用在所测试的制剂中最为显着且作用时间长,可以通过在整个研究过程中从10到120分钟的最大可能的最大作用来得出结论。结论:TPGS / LID-NLC的最突出的体外渗透效率和体内麻醉作用可能是TPGS修饰的NLC可以作为长期有效的局部麻醉治疗的有希望的药物递送系统的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号